Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CONMED Corporation (CNMD : NYSE)

• Company Description    CONMED Corporation is a major medical products manufacturer specializing in surgical instruments and devices for minimally invasive procedures and monitoring. A significant portion of the company's revenues are derived from products designed for the orthopedic surgery markets of arthroscopy and powered surgical instruments. The company also sells products for general and other surgical specialties such as electrosurgery systems for all types of surgery, and endosurgery instruments for minimally invasive laparoscopic surgery. Patient Care products, including ECG electrodes for heart monitoring and pulse oximetry for blood oxygenation monitoring, are provided for various clinical settings.The company operates in two revenue segments: Orthopedic Surgery and General Surgery. Number of Employees: 3,900

• Price / Volume Information    Yesterday's Closing Price: $54.33 Daily Weekly Monthly 20 Day Moving Average: 401,095 shares Shares Outstanding: 30.94 (millions) Market Capitalization: $1,680.96 (millions) Beta: 1.20 52 Week High: $78.19 52 Week Low: $46.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.04% -9.24% 12 Week 3.90% -12.83% Year To Date -20.62% -25.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11311 CONCEPT BOULEVARD - LARGO,FL 33773 USA ph: 727-392-6464 fax: 315-797-0321 None http://www.conmed.com

• General Corporate Information    Officers Patrick J. Beyer - President and Chief Executive Officer Martha Goldberg Aronson - Chairman Todd W. Garner - Executive Vice President; Finance and Chief Financ David Bronson - Director Brian P. Concannon - Director Peer Information CONMED Corporation (ITRJ) CONMED Corporation (BRLI.) CONMED Corporation (GOGY) CONMED Corporation (PSTX.) CONMED Corporation (ELGXQ) CONMED Corporation (CAH) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED/DENTAL-SUPP Sector: Medical CUSIP: 207410101 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/30/25 Share - Related Items Shares Outstanding: 30.94 Most Recent Split Date: 9.00 (1.50:1) Beta: 1.20 Market Capitalization: $1,680.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 1.47% Current Fiscal Quarter EPS Consensus Estimate: $1.01 Indicated Annual Dividend: $0.80 Current Fiscal Year EPS Consensus Estimate: $4.42 Payout Ratio: 0.19 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: -0.09 Estmated Long-Term EPS Growth Rate: 8.80% Last Dividend Paid: 06/13/2025 - $0.20 Next EPS Report Date: 07/30/25

• Fundamental Ratios P/E Current FY Estimate: 12.30 Trailing 12 Months: 12.58 PEG Ratio: 1.40 Price Ratios Price/Book: 1.72 Price/Cash Flow: 8.09 Price / Sales: 1.28 EPS Growth vs. Year Ago Period: 20.25% vs. Previous Quarter: -29.10% Sales Growth vs. Year Ago Period: 2.88% vs. Previous Quarter: -7.14% ROE 06/30/25 - - 03/31/25 - 14.36 12/31/24 - 14.31 ROA 06/30/25 - - 03/31/25 - 5.86 12/31/24 - 5.64 Current Ratio 06/30/25 - - 03/31/25 - 2.26 12/31/24 - 2.30 Quick Ratio 06/30/25 - - 03/31/25 - 1.00 12/31/24 - 1.05 Operating Margin 06/30/25 - - 03/31/25 - 10.24 12/31/24 - 9.94 Net Margin 06/30/25 - - 03/31/25 - 9.02 12/31/24 - 10.13 Pre-Tax Margin 06/30/25 - - 03/31/25 - 11.04 12/31/24 - 12.47 Book Value 06/30/25 - - 03/31/25 - 31.60 12/31/24 - 31.16 Inventory Turnover 06/30/25 - - 03/31/25 - 1.69 12/31/24 - 1.72 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.91 12/31/24 - 0.94 Debt-to-Capital 06/30/25 - - 03/31/25 - 47.69 12/31/24 - 48.46

Powered by Zacks Investment Research ©